SERPINA5 · Western blot design guide

SERPINA5 Western Blot Planning Guide

Plan a SERPINA5 Western blot around the catalog-observed 45.7 kDa band, image-backed A01916-1 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for SERPINA5 (SERPINA5): expected band 45.7 kDa, antibody A01916-1, and guide-derived SDS-PAGE protocol steps
SERPINA5 Western blot protocol sheet — expected band 45.7 kDa, antibody A01916-1, controls and PMC citations. Open the full SERPINA5 WB guide →

SERPINA5 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 45.7 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Adrenal gland
Negative control ⓘ Cerebral cortex
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 45.7 kDa
ⓘ Localization Secreted, extracellular space
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated SERPINA5 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAdrenal gland
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA01916-1 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected SERPINA5 Western Blot Band Size?

Use the product-observed 45.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
45.7 kDaMatches the authoritative product WB observation.
45.7 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected SERPINA5 appearancePlan around 45.7 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band45.7 kDa; use this as the primary experimental expectation.
Calculated mass45.7 kDa from UniProt P05154; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A01916-1.
Why is my band missing or off?
SituationLikely causeNext action
45.7 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for SERPINA5 Western blot

🧪Use Adrenal gland as the first positive-control candidate and Cerebral cortex as the HPA Not detected negative candidate.
Positive control: Adrenal gland (High)
Negative control: Cerebral cortex (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for SERPINA5

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Adrenal gland Reported tissue cells High Protein (HPA) HPA →
Kidney Reported tissue cells High Protein (HPA) HPA →
Cervix Reported tissue cells High Protein (HPA) HPA →
Endometrium Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Cerebral cortex Reported tissue cells Not detected Protein (HPA) HPA →
Cerebellum Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced SERPINA5 Western Blot Tips

Deeper troubleshooting and optimisation questions for SERPINA5, answered from its protein features.

Which band should guide the blot?
Use 45.7 kDa, the observation attached to the authoritative A01916-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 45.7 kDa expectation.
Which positive control should I start with?
Start with Adrenal gland, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Cerebral cortex as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SERPINA5 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01916-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

SERPINA5 Western Blot Reagents

Human/Mouse/Rat-reactive SERPINA5 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for SERPINA5 using A01916-1; observed band 45.7 kDa
Anti-Protein C inhibitor/SERPINA5 Antibody Picoband®
Cat # A01916-1

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P05154
  2. Human Protein Atlas — SERPINA5
  3. A01916-1 product record
  4. PMC9465189 — SERPINA5 promotes tumour cell proliferation by modulating the PI3K/AKT/mTOR signalling pathway in gastric cancer (Journal of cellular and molecular medicine, 2022)
  5. PMC10049297 — IFN-Inducible SerpinA5 Triggers Antiviral Immunity by Regulating STAT1 Phosphorylation and Nuclear Translocation (International journal of molecular sciences, 2023)